Shots: Seattle Genetics and Astellas sign a clinical trial agreement with Merck to evaluate the combination of Seattle Genetics’ and Astellas’ ADC and Merck’s anti-PD-1 therapy in patients with previously […]readmore
Tags : Metastatic Urothelial Cancer
Shots: The BLA submission is based on EV-201 P-II clinical study assessing Enfortumab Vedotin in patients with LA/m- urothelial cancer prior treated with PD-1/L1 inhibitor, including patients treated/not treated with […]readmore